(Yicai) Sept. 19 -- Kangtai Biological Products has partnered with leading Indian and Pakistani drugmakers to register, market, and sell the Chinese vaccine maker’s varicella jab in the two Asian countries.

Kangtai’s unit Minhai Biotechnology recently signed authorized agency agreements with two well-known Indian and Pakistani drugmakers to sell its attenuated vaccine against varicella in the two countries, the Shenzhen-based company announced on its official WeChat account today.

The varicella jab is used on people over one year old and susceptible to chickenpox. It can stimulate the human body to produce immunity against the varicella-zoster virus.

India is the most populous country, with a population of around 1.4 billion, while Pakistan has a population of about 241 million, the world’s fifth-biggest, according to data from the United Nations. India had a new-born population of 23 million last year, and Pakistan of 6.4 million. Therefore, the two countries have great potential for varicella vaccines, which mainly target children.

Kangtai applied to register its live attenuated vaccine against varicella in China and completed verification at the registration site and examination about conformity with the Good Manufacturing Practice, the company noted.

BCHT Biotechnology is China’s leading varicella vaccine maker, as its varicella jab occupies an over 30 percent share of the Chinese market. Eighty-nine percent of the Changchun-based firm’s operating revenue came from the varicella vaccine business last year.

Editor: Futura Costaglione